The estimated Net Worth of Frederick W Driscoll is at least $2.28 Million dollars as of 3 September 2021. Mr. Driscoll owns over 19,417 units of NantKwest Inc stock worth over $630,858 and over the last 15 years he sold NK stock worth over $1,436,446. In addition, he makes $208,288 as Lead Independent Director at NantKwest Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Driscoll NK stock SEC Form 4 insiders trading
Frederick has made over 11 trades of the NantKwest Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 19,417 units of NK stock worth $20,194 on 3 September 2021.
The largest trade he's ever made was selling 65,300 units of NantKwest Inc stock on 11 August 2020 worth over $668,019. On average, Frederick trades about 4,339 units every 67 days since 2009. As of 3 September 2021 he still owns at least 19,417 units of NantKwest Inc stock.
You can see the complete history of Mr. Driscoll stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Frederick Driscoll biography
Frederick W. Driscoll serves as Lead Independent Director of the Company. He has served as a member of our board of directors since September 2017. Mr. Driscoll served as Chief Financial Officer at Flexion Therapeutics, Inc., a publicly traded specialty pharmaceutical company, from 2013 until his retirement in March 2017. Prior to Flexion, he was Chief Financial Officer at Novavax, Inc., a publicly traded biopharmaceutical company, from 2009 to 2013. From 2008 to 2009, Mr. Driscoll served as Chief Executive Officer of Genelabs Technologies, Inc., a publicly traded biopharmaceutical and diagnostics company later acquired by GlaxoSmithKline. He previously served as Genelabs’ Chief Financial Officer from 2007 to 2008. From 2000 to 2006, Mr. Driscoll served as Chief Executive Officer at OXiGENE, Inc., a biopharmaceutical company. Mr. Driscoll has also served as Chairman of the Board and Audit Committee Chair at OXiGENE and as a member of the Audit Committee for Cynapsus Therapeutics, Inc., which was sold to Sunovion Pharmaceuticals in 2016. Mr. Driscoll currently serves on the boards of MEI Pharma, Inc., Cue Biotherapeutics, Inc. and Cellectar Biosciences, Inc. He earned a Bachelor’s degree in accounting and finance from Bentley University.
What is the salary of Frederick Driscoll?
As the Lead Independent Director of NantKwest Inc, the total compensation of Frederick Driscoll at NantKwest Inc is $208,288. There are 4 executives at NantKwest Inc getting paid more, with Barry Simon having the highest compensation of $454,440.
How old is Frederick Driscoll?
Frederick Driscoll is 69, he's been the Lead Independent Director of NantKwest Inc since 2019. There are no older and 7 younger executives at NantKwest Inc.
What's Frederick Driscoll's mailing address?
Frederick's mailing address filed with the SEC is C/O CELLECTAR BIOSCIENCES, INC., 100 CAMPUS DRIVE, FLORHAM PARK, NJ, 07932.
Insiders trading at NantKwest Inc
Over the last 9 years, insiders at NantKwest Inc have traded over $20,345,739 worth of NantKwest Inc stock and bought 4,163,265 units worth $55,365,252 . The most active insiders traders include Patrick Cambridge Equities,..., Steve Gorlin, and Barry J. Simon. On average, NantKwest Inc executives and independent directors trade stock every 33 days with the average trade being worth of $5,362,832. The most recent stock trade was executed by Richard Adcock on 5 February 2021, trading 150,000 units of NK stock currently worth $4,873,500.
What does NantKwest Inc do?
NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.
What does NantKwest Inc's logo look like?
Complete history of Mr. Driscoll stock trades at Cellectar Biosciences Inc, Flexion Therapeutics Inc, MEI Pharma Inc, NantKwest Inc, Novavax, and Cue Biopharma Inc
NantKwest Inc executives and stock owners
NantKwest Inc executives and other stock owners filed with the SEC include:
-
Barry Simon,
President, Chief Administrative Officer, Director -
Sonja Nelson,
Chief Financial Officer -
Cheryl Cohen,
Director -
Patrick Soon-Shiong,
Executive Chairman of the Board -
Frederick Driscoll,
Lead Independent Director -
John Thomas,
Independent Director -
Michael Blaszyk,
Independent Director -
Richard Adcock,
Chief Executive Officer -
John T Jr Potts,
Director -
Richard Kusserow,
Director -
Angela Wilson,
Chief Financial Officer -
Steve Gorlin,
Director -
Richard J. Tajak,
Chief Financial Officer -
Patrickmp 13 Ventures, Llc ...,
Chairman and CEO -
Patrick Chan Soon Shiong Fa...,
Chairman and CEO